6:00 PM
Feb 01, 2013
 |  BC Extra  |  Financial News

Merck delaying odanacatib submissions

Merck & Co. Inc. (NYSE:MRK) disclosed in its 4Q12 and 2012 earnings that it will delay to 2014 from 1H13 the expected submission of regulatory applications in the U.S., EU and Japan for odanacatib to treat osteoporosis. The pharma said the delay is a result of its decision to include data from about 8,200 women in a double-blind extension of a Phase III trial for the cathepsin K...

Read the full 321 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >